Superior Anti-tumor Efficacy of Bicalutamide 80 mg in Combination with a Luteinizing Hormone-releasing Hormone (LHRH) Agonist Versus LHRH Agonist Monotherapy as First-line Treatment for Advanced Prostate Cancer: Interim Results of a Randomized Study in Japanese Patients

Randomized Study ◽

Japanese Patients ◽

Lhrh Agonist ◽

Line Treatment ◽

First Line ◽

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients

Prostate Cancer and Prostatic Diseases ◽

10.1038/sj.pcan.4500934 ◽

2007 ◽

Vol 10 (2) ◽

pp. 194-201 ◽

Cited By ~ 26

Author(s):

M Usami ◽

H Akaza ◽

Y Arai ◽

Y Hirano ◽

S Kagawa ◽

...

Keyword(s):

Prostate Cancer ◽

Luteinizing Hormone ◽

Japanese Patients ◽

Multicenter Trial ◽

Phase Iii ◽

Double Blind ◽

PROSPECTIVE DETERMINATION OF THE HORMONAL AND BIOCHEMICAL RESPONSE FOLLOWING LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AGONIST WITHDRAWAL IN PATIENTS WITH ADVANCED PROSTATE CANCER

The Journal of Urology ◽

10.1097/00005392-199904010-00712 ◽

1999 ◽

pp. 177

Author(s):

Ralph J. Fritzsch ◽

Claus G. Roehrborn ◽

Allison Ahrens ◽

Arthur I. Sagalowsky ◽

M. Craig Hall

Keyword(s):

Prostate Cancer ◽

Luteinizing Hormone ◽

Biochemical Response ◽

Lhrh Agonist ◽

Faculty Opinions recommendation of Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14267095.15779304 ◽

2012 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Prostate Cancer ◽

Luteinizing Hormone ◽

Biochemical Recurrence ◽

Second Line ◽

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology ◽

10.1016/j.eururo.2007.02.060 ◽

2007 ◽

Vol 52 (4) ◽

pp. 1020-1027 ◽

Cited By ~ 13

Author(s):

Giuseppe Di Lorenzo ◽

Riccardo Autorino ◽

Sisto Perdonà ◽

Michele De Laurentiis ◽

Massimo D'Armiento ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Line Treatment ◽

First Line ◽

Hormone Refractory ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2020.05.003 ◽

2020 ◽

Vol 18 (6) ◽

pp. 425-428 ◽

Cited By ~ 1

Author(s):

Jacob J. Adashek ◽

Jarred P. Reed ◽

Ankita Tandon ◽

Stephen J. Freedland ◽

Edwin Posadas ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Line Treatment ◽

First Line ◽

Receptor Inhibition ◽

Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist

Urology ◽

10.1016/0090-4295(93)90265-c ◽

1993 ◽

Vol 42 (5) ◽

pp. 533-535 ◽

Cited By ~ 12

Author(s):

J.Anthony Shaheen ◽

Mohammad Amin ◽

James I. Harty

Keyword(s):

Prostate Cancer ◽

Luteinizing Hormone ◽

Patient Compliance ◽

Lhrh Agonist ◽

Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer

European Urology ◽

10.1016/j.eururo.2004.08.022 ◽

2004 ◽

Vol 46 (6) ◽

pp. 712-716 ◽

Cited By ~ 14

Author(s):

Giuseppe Di Lorenzo ◽

Carmine Pizza ◽

Riccardo Autorino ◽

Michele De Laurentiis ◽

Ombretta Marano ◽

...

Keyword(s):

Prostate Cancer ◽

Hormone Refractory Prostate Cancer ◽

Line Treatment ◽

First Line ◽

Weekly Docetaxel ◽

Hormone Refractory ◽

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

Urology ◽

10.1016/s0090-4295(99)80368-9 ◽

1995 ◽

Vol 46 (6) ◽

pp. 899 ◽

Cited By ~ 2

Author(s):

E. David Crawford

Keyword(s):

Prostate Cancer ◽

Luteinizing Hormone ◽

Controlled Trial ◽

Hormone Analogue ◽

Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer

Molecular and Clinical Oncology ◽

10.3892/mco.2013.205 ◽

2013 ◽

Vol 2 (1) ◽

pp. 134-138 ◽

Cited By ~ 4

Author(s):

YASUTAKE UCHIMA ◽

TAKAFUMI NISHII ◽

YASUHITO ISEKI ◽

MARIKO ISHII ◽

SOICHIRO HIRAMATSU ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Retrospective Analysis ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽